HealthCor Management L.P. lowered its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 36.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 400,000 shares of the biopharmaceutical company’s stock after selling 225,000 shares during the period. Regeneron Pharmaceuticals comprises 5.4% of HealthCor Management L.P.’s investment portfolio, making the stock its 4th biggest position. HealthCor Management L.P. owned about 0.37% of Regeneron Pharmaceuticals worth $161,616,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently added to or reduced their stakes in the company. Capital World Investors increased its stake in shares of Regeneron Pharmaceuticals by 5.3% during the third quarter. Capital World Investors now owns 6,384,323 shares of the biopharmaceutical company’s stock worth $2,579,522,000 after purchasing an additional 322,051 shares in the last quarter. FMR LLC increased its stake in shares of Regeneron Pharmaceuticals by 17.0% during the third quarter. FMR LLC now owns 5,016,501 shares of the biopharmaceutical company’s stock worth $2,026,867,000 after purchasing an additional 728,104 shares in the last quarter. Loomis Sayles & Co. L P increased its stake in shares of Regeneron Pharmaceuticals by 1.2% during the third quarter. Loomis Sayles & Co. L P now owns 3,346,280 shares of the biopharmaceutical company’s stock worth $1,352,031,000 after purchasing an additional 41,138 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Regeneron Pharmaceuticals by 12.7% during the second quarter. Janus Henderson Group PLC now owns 1,802,740 shares of the biopharmaceutical company’s stock worth $621,927,000 after purchasing an additional 203,306 shares in the last quarter. Finally, Capital International Investors purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $703,075,000. 67.24% of the stock is owned by institutional investors and hedge funds.
In other news, Director Michael S. Brown sold 2,000 shares of the stock in a transaction that occurred on Thursday, September 27th. The shares were sold at an average price of $392.26, for a total value of $784,520.00. Following the completion of the sale, the director now owns 2,000 shares of the company’s stock, valued at approximately $784,520. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last three months, insiders sold 4,006 shares of company stock valued at $1,564,114. Corporate insiders own 12.42% of the company’s stock.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share for the quarter, beating the consensus estimate of $4.94 by $0.93. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The business had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same quarter in the prior year, the company posted $3.99 EPS. The business’s revenue for the quarter was up 10.8% on a year-over-year basis. As a group, equities analysts forecast that Regeneron Pharmaceuticals Inc will post 18.88 earnings per share for the current fiscal year.
REGN has been the subject of several research reports. Cantor Fitzgerald upped their price objective on shares of Regeneron Pharmaceuticals to $441.00 and gave the company a “neutral” rating in a research note on Monday, October 22nd. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $409.00 to $412.00 and gave the company an “equal weight” rating in a research note on Thursday, October 11th. BidaskClub cut shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, November 16th. JPMorgan Chase & Co. set a $405.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday, November 7th. Finally, Oppenheimer set a $440.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, December 2nd. One research analyst has rated the stock with a sell rating, seventeen have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $406.89.
TRADEMARK VIOLATION NOTICE: “HealthCor Management L.P. Sells 225,000 Shares of Regeneron Pharmaceuticals Inc (REGN)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.com-unik.info/2018/12/16/healthcor-management-l-p-sells-225000-shares-of-regeneron-pharmaceuticals-inc-regn.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: Put Option
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.